Stablepharma appoints Professor Saul Faust, University of Southampton, to the Advisory BoardStablepharma partners with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology
StablevaX™ - a vital complementary technology for vaccines
Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. A stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.
Stablepharma’s strategy is to initially target the T&D containing vaccines. We have signed an R&D and Commercial LoI with the European WHO pre-qualified vaccine manufacturer Bul Bio in order to thermo-stabilise their Tetadif (Td) vaccine.
Stablepharma also recently initiated a programme on thermostability of naked SARS-COV-2 mRNA as well as lipid nano-particle (LNP) containing the SARS-COV-2 mRNA. Our aim is to demonstrate that our novel technology StablevaX™ can stabilise the mRNA and LNP to be stored and transported in higher temperatures.
Latest Press Coverage StablevaX™
The WHO state that roughly 50% of vaccines are wasted due mostly to failures in the cold chain. Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature.
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
StablevaX™ technology aims to eliminate the need for refrigeration
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.